Evidence map›Paper›PMID 40399554›Full record

ArticleNature genetics2025

Genomic landscape of multiple myeloma and its precursor conditions.

Jean-Baptiste Alberge, Ankit K Dutta, Andrea Poletti, Tim H H Coorens, Elizabeth D Lightbody, Rosa Toenges, Xavi Loinaz, Sofia Wallin, Andrew Dunford, Oliver Priebe and 28 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Genomics Define Malignant Transformation in Myeloma Precursor Conditions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026
    Article
  14. Review
  15. Article
  16. Mutational signatures in hematological malignancies.Einstein (Sao Paulo, Brazil) · 2026
    Review
  17. Karyotype evolution of multiple myeloma.Journal of clinical and experimental hematopathology : JCEH · 2026
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Jean-Baptiste Alberge *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-4218-7294
Ankit K Dutta *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrea Poletti *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0753-1248
Tim H H CoorensCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-5826-3554
Elizabeth D LightbodyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rosa ToengesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Xavi LoinazCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0009-0002-4999-2605
Sofia WallinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Andrew DunfordCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Oliver PriebeCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Johnathan DaganCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Cody J BoehnerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Erica HorowitzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nang K SuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hadley BarrDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Laura HevenorDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Katherine TowleDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rashmika BeesamDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jenna B BeckwithDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jacqueline PerryDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
David M Cordas Dos SantosDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9198-8338
Luca BertaminiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Patricia T GreippDepartment of Laboratory Medicine and Pathology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-5536-9011
Kirsten KüblerCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0342-5579
Peter F ArndtDepartment of Computational Molecular Biology, Max Planck Institute for Molecular Genetics, Berlin, Germany.ORCID http://orcid.org/0000-0003-1762-9836
Carolina TerragnaIRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
Elena ZamagniDepartment of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Eileen M BoyleDepartment of Haematology, Cancer Institute, University College London Cancer Institute, London, UK.
Kwee YongDepartment of Haematology, Cancer Institute, University College London Cancer Institute, London, UK.
Gareth MorganMyeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.ORCID http://orcid.org/0000-0002-4271-6360
Brian A WalkerMelvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0002-8615-6254
Meletios Athanasios DimopoulosDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0001-8990-3254
Efstathios KastritisDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Julian HessCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-1387-4009
Romanos Sklavenitis-PistofidisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Chip StewartCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Gad GetzCancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA. gadgetz@broadinstitute.org.ORCID http://orcid.org/0000-0002-0936-0753
Irene M GhobrialDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. irene_ghobrial@dfci.harvard.edu.ORCID http://orcid.org/0000-0001-7361-3092

Funding

Molecular Prediction of Myeloma Initiation Molecular Prediction of Myeloma InitiationR35CA263817 · NCI · DANA-FARBER CANCER INST · PI Irene M. Ghobrial · 2022 to 2026
$5.1M
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (Dr. Miriam & Sheldon G. Adelson Medical Research Foundation)EIF | Stand Up To Cancer (SU2C) SU2C-AACR-DT-28-18Multiple Myeloma Research Foundation (Multiple Myeloma Research Foundation, Inc.)NCI NIH HHS R35 CA263817
6 · The paper itself

Abstract

Reliable strategies to capture patients at risk of progression from precursor stages of multiple myeloma (MM) to overt disease are still missing. We assembled a comprehensive collection of MM genomic data comprising 1,030 patients (218 with precursor conditions) that we used to identify recurrent coding and non-coding candidate drivers as well as significant hotspots of structural variation. We used those drivers to define and validate a simple 'MM-like' score, which we could use to place patients' tumors on a gradual axis of progression toward active disease. Our MM precursor genomic map provides insights into the time of initiation and cell-of-origin of the disease, order of acquisition of genomic alterations and mutational processes found across the stages of transformation. Taken together, we highlight here the potential of genome sequencing to better inform risk assessment and monitoring of MM precursor conditions.

Indexed as

GenomicsMultiple MyelomaPrecancerous ConditionsDisease ProgressionGenome, HumanHumansMutation

Identifiers

PMID40399554
PMCPMC12165861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.